HAB Pharma, Signature Phytochemicals merge to form Rs. 600 crore integrated pharma entity

Combined company targets Rs. 2,500–3,000 crore revenue by 2030; new sterile and OSD plants to begin operations by August 2026

Gland Pharma posts record revenue, nearly doubles profit in Q4 FY26

The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment

Senores Pharma doubles profit as sales surge 62%

Global specialty pipeline accelerates growth

Neuland Laboratories posts blockbuster FY26 performance

Lonza surges on biologics boom

Expands manufacturing push & locks in major growth deals

Novartis locks in $23 billion US expansion with seventh new facility

The latest addition, a new API facility in Morrisville, North Carolina, will produce key components for solid dosage tablets, capsules, and RNA therapeutics

Patient-centric innovation driving fight against neglected diseases: Sanjay Sarin, Continental Lead Asia and South Asia Director, DNDi

While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules

NADMED Limited appoints James Lee as CEO to drive global expansion

Former Novo Nordisk and Pharmanovia executive to lead next growth phase in NAD diagnostics and personalised health innovation

Sun Pharma eyes biosimilars-led growth, Organon deal to build $12.4 billion global platform

On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms

Biosimilars gain momentum as US market sees 92 approvals: Samsung Bioepis report

Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation